Merck plans a Phase 3 trial of Winrevair after a Phase 2 study testing it in CpcPH due to HFpEF hit its main goal.

Winrevair, which Merck has identified as a “growth driver,” significantly improved blood flow through the lungs to the heart ...

Merck , known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 2 CADENCE study evaluating WINREVAIRtm (sotatercept-csrk) in adults for the ...

Doctors in Thane at Jupiter Hospital successfully performed a life-saving Transcatheter Aortic Valve Implantation (TAVI) on a 69-year-old male patient ...

Tempus AI shows strong Q3 growth with 85% higher sales, robust oncology and data licensing momentum, and attractive 7.5x ’26 ...

The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.

Trastuzumab emtansine is linked to a lower incidence of decrease in left ventricular ejection fraction than other trastuzumab ...

Adults with heart failure with reduced ejection fraction (HFrEF) who took a "polypill" combining medications prescribed for the treatment of heart failure, had improved heart function and symptoms, ...

A polypill containing three recommended heart failure therapies improved heart function, reduced hospitalizations and was ...

Despite making up half of the 64 million people living with heart failure, patients with this common form have no access to ...

Adults with heart failure with reduced ejection fraction (HFrEF) who took a "polypill" combining medications prescribed for ...